We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Biomedical Engineering/Characterization of Synthesized NANO−encapsulated Drug for Bone Loss on Hind Limb Suspension Rat Model by NMR and Micro-CT
PeriodicalsBiomedical Engineering

Characterization of Synthesized NANO−encapsulated Drug for Bone Loss on Hind Limb Suspension Rat Model by NMR and Micro-CT

Checking your access to this record.

Abstract & Overview

A formulation of nano-encapsulated enantiomer of (+) promethazine with desired release rate has been synthesized for establish a localized drug delivery system. It was tested on a hind limb suspension (HLS) disuse rat model, and by using a non-destructive Nuclear Magnetic Resonance (NMR) relaxation technique, and micro computed tomography (Micro-CT) analysis technique to qualitatively evaluate the effectiveness of the new bone formations as well as to compare the current commercial anti-bone loss drug Alendeonate. Our studies suggest that nano-encapsulated (+) promethazine in controlled release formulations conjugating bone-targeting functional groups are effective in promoting bone growth in a disuse rat model.

Cite this record

Qingwen Ni (2013). Characterization of Synthesized NANO−encapsulated Drug for Bone Loss on Hind Limb Suspension Rat Model by NMR and Micro-CT. Advances in Bioscience and Bioengineering, 1(1), 1–1. https://doi.org/10.11648/j.abb.20130101.11

Copy in another style

Ni, Q. (2013). Characterization of Synthesized NANO−encapsulated Drug for Bone Loss on Hind Limb Suspension Rat Model by NMR and Micro-CT. Advances in Bioscience and Bioengineering, 1(1), 1–1. https://doi.org/10.11648/j.abb.20130101.11
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.